Inhibition of Bromodomain and Extra-Terminal Proteins (BET) as a Potential Therapeutic Approach in Haematological Malignancies: Emerging Preclinical and Clinical Evidence

Therapeutic Advances in Hematology - United States
doi 10.1177/2040620715576662
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

SAGE Publications

Related search

Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-Terminal Domain (BET) Proteins

English

Synergistic Induction of Cell Death in Haematological Malignancies by Combined Phosphoinositide-3-Kinase and BET Bromodomain Inhibition

British Journal of Haematology
Hematology
2015English

BET Bromodomain Proteins Are Therapeutic Targets in CRPC

Cancer Discovery
Oncology
2014English

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2016English

Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-Dominant Allergic Airway Disease

Scientific Reports
Multidisciplinary
2017English

Suppression of Interferon Β Gene Transcription by Inhibitors of Bromodomain and Extra-Terminal (BET) Family Members

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2015English

EZH2 as a Therapeutic Target for Multiple Myeloma and Other Haematological Malignancies

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2018English

Bromodomain and Extraterminal (BET) Proteins Regulate Biliary-Driven Liver Regeneration

Journal of Hepatology
Hepatology
2016English

Preclinical Evidence of Ghrelin as a Therapeutic Target in Epilepsy

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy